The GOG-240 trial established the survival benefit of adding bevacizumab to chemotherapy in recurrent or metastatic cervical cancer. Bevacizumab targets which molecular pathway?
- A VEGF-A angiogenesis pathway ✓
- B PD-L1/PD-1 immune checkpoint
- C EGFR tyrosine kinase signalling
- D mTOR/PI3K proliferation cascade
Correct answer: A. VEGF-A angiogenesis pathway
Explanation
Bevacizumab is a monoclonal antibody targeting VEGF-A (vascular endothelial growth factor A), thereby inhibiting tumour angiogenesis. The GOG-240 trial (2014) showed that adding bevacizumab to cisplatin-paclitaxel or topotecan-paclitaxel in recurrent/metastatic cervical cancer significantly improved overall survival (17 vs 13.3 months, HR 0.71). Pembrolizumab targets PD-1; cetuximab targets EGFR; temsirolimus targets mTOR.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.